Literature DB >> 69193

25-hydroxy-vitamin-D in nephrotic syndrome.

H Schmidt-Gayk, C Grawunder, W Tschöpe, W Schmitt, E Ritz, V Pietsch, K Andrassay, R Bouillon.   

Abstract

Serum-25-hydroxy-vitamin-D (25-OHD) nephrotic syndrome (N.S.) without renal insufficiency (urinary protein excretion greater than 3-5 g/24 h/1-73 m2; glomerular filtration-rate greater than 80 ml/min/1-73 m2). Serum-25-OHD levels were low in patients with N.S. (mean 19 nmol/1, range 4-41 nmol/1), compared with a normal range of 25-200 nmol/1. Serum-concentrations of Gc-globulin--the binding protein for vitamin D and its metabolites (D.B.P.)--were significantly (P less than 0-001) lower in patients with N.S. (mean 340 mg/1, range 190-480 mg/1) than in non-proteinuric controls (mean 440 mg/1, range 376-510 mg/1, measured by radial immunodiffusion). In contrast to non-proteinuric urine, urine of all N.S. patients contained a large amount of 25-OHD-binding capacity; D.B.P. could be detected in all N.S. urines after concentration. Scatchard analysis of the urine demonstrated the presence of a low-affinity and a high-affinity binding protein (tentatively identified as albumin and D.B.P.). These results suggest an acquired deficiency of circulating 25-OHD in N.S. secondary to urinary loss of protein-bound 25-OHD. The biological relevance of the low 25-OHD levels is unknown. There was no clinical evidence of osteomalacia (X-ray, serum-alkaline-phosphatase); however, slightly elevated serum-parathyroid-hormone (P.T.H.) levels would be compatible with borderline vitamin-D depletion.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 69193     DOI: 10.1016/s0140-6736(77)90118-0

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  20 in total

1.  Is it correct to supplement patients with nephrotic syndrome with vitamin D and calcium?

Authors:  O Mehls
Journal:  Pediatr Nephrol       Date:  1990-09       Impact factor: 3.714

2.  Ethnic differences in 25-hydroxyvitamin D levels and response to treatment in CKD.

Authors:  Iris Sanchez; Roberto Mangoo-Karim; Jason R Stubbs; George P Yanev; James B Wetmore
Journal:  Int Urol Nephrol       Date:  2012-05-30       Impact factor: 2.370

Review 3.  The clinical use of vitamin D metabolites and their potential developments: a position statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF).

Authors:  Luisella Cianferotti; Claudio Cricelli; John A Kanis; Ranuccio Nuti; Jean-Y Reginster; Johann D Ringe; Rene Rizzoli; Maria Luisa Brandi
Journal:  Endocrine       Date:  2015-05-01       Impact factor: 3.633

4.  Disease activity, proteinuria, and vitamin D status in children with systemic lupus erythematosus and juvenile dermatomyositis.

Authors:  Angela Byun Robinson; Myrtle Thierry-Palmer; Keisha L Gibson; Consuelo Egla Rabinovich
Journal:  J Pediatr       Date:  2011-09-15       Impact factor: 4.406

5.  Do patients who are treated with calcitriol for renal osteodystrophy also need vitamin D3 therapy?

Authors:  O Mehls
Journal:  Pediatr Nephrol       Date:  1995-04       Impact factor: 3.714

Review 6.  Bone Health in Glomerular Kidney Disease.

Authors:  Dorey A Glenn; Michelle R Denburg
Journal:  Curr Osteoporos Rep       Date:  2019-12       Impact factor: 5.096

7.  Free 1,25-dihydroxyvitamin D levels in serum from normal subjects, pregnant subjects, and subjects with liver disease.

Authors:  D D Bikle; E Gee; B Halloran; J G Haddad
Journal:  J Clin Invest       Date:  1984-12       Impact factor: 14.808

8.  Osteomalacia and hyperparathyroid bone disease in patients with nephrotic syndrome.

Authors:  H H Malluche; D A Goldstein; S G Massry
Journal:  J Clin Invest       Date:  1979-03       Impact factor: 14.808

Review 9.  Vitamin D and glucose metabolism in chronic kidney disease.

Authors:  Ian H de Boer
Journal:  Curr Opin Nephrol Hypertens       Date:  2008-11       Impact factor: 2.894

10.  Pattern of growth hormone response to insulin, arginine and haemodialysis in uraemic children.

Authors:  K Ijaiya
Journal:  Eur J Pediatr       Date:  1979-06-28       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.